Migraine drug shows promise for IBS belly pain in small study

NCT ID NCT06221111

Completed Symptom relief Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested whether rimegepant (Nurtec), a drug used for migraines, can reduce chronic abdominal pain in people with irritable bowel syndrome (IBS). Thirty-nine adults with non-constipation IBS took either the drug or a placebo for 28 days. Researchers measured changes in daily pain scores using a 100-point scale, along with bowel movement frequency and rectal function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rimegepant (Nurtec)
What this could lead to: If it works, this could point toward a new option for easing chronic abdominal pain in people with irritable bowel syndrome.
What could go wrong: This is a small, early pilot study with only 39 participants. The results may not apply to everyone, and the drug might not prove effective in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IRRITABLE BOWEL SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

irritable bowel syndrome Pain superficial epidermolytic ichthyosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IRRITABLE BOWEL SYNDROME

Contacts and locations

Show contact details

Locations

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.